Y-mAbs Therapeutics Inc.’s statistical arguments could not convince the US Food and Drug Administration’s Oncologic Drugs Advisory Committee that its I-omburtamab was effective in neuroblastoma, just like it did not sway the agency reviewers.
But advisory committee members indicated that the ground-breaking work Y-mAbs and the FDA are undertaking using real-world data could eventually...